VolitionRX Ltd (AMEX:VNRX)
$ 0.72 -0.0071 (-0.98%) Market Cap: 59.63 Mil Enterprise Value: 54.00 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

VolitionRX Ltd To Present At GCFF Transcript

Sep 10, 2020 / NTS GMT
Release Date Price: $3.16 (-0.94%)
Scott Powell
VolitionRx Limited - IR, CFO, Volition America, Inc.

We are VolitionRX. Ticker is BNRX on the New York Stock Exchange, American Stock Exchange. I will be making some forward-looking statements. So I do point you to the forward-looking statements and disclaimer. And a little bit about Volition. Volition is simple. We want to save lives.

We are a diagnostics company, developing blood tests to screen primarily for different cancer types. But As Gilbert mentioned, we are also developing a blood test for a noncancer indication [of] COVID-19. And I'll talk a little bit about that product because the coronavirus is front and center for most of us these days.

So here, you can see a little bit about our COVID-19 product development, developing a blood tests for this particular virus. We are not developing a frontline blood test for the coronavirus. There are a number of FDA approved frontline screens for the coronavirus already in use in the United States.

What we are planning to develop is a triage or a risk stratification blood test to be given to patients who have had a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot